The antibody responses of novel chimeric peptide vaccine against HTLV-۱ in the absence or presence of various immunostimulatory adjuvants

This study aimed to immunogenicity assessment of a novel chimeric peptide vaccine against human T-cell lymphotropic virus type ۱ (HTLV-۱) through subcutaneous (SC) or intranasal administration in a mice model. Additionally, to elevate the efficacy of the HTLV-۱ vaccine, the chimera was physically mixed with monophosphoryl lipid A (MPLA) or ISCOMATRIX (IMX) adjuvants. For this purpose, the ISCOMATRIX with a size range of ۴۰–۶۰ nm were prepared using the lipid film hydration method. Our investigation revealed that the mixture of IMX and chimera could significantly enhance IgG۲a and mucosal IgA antibody titers. The nasal delivery of chimera vaccine in the absence or presence of adjuvants stimulated potent mucosal sIgA titer relative to subcutaneous immunization. Our findings suggest that proper design, construction, and immunization of multi-epitope vaccines are essential for developing an effective HTLV-۱ vaccine

کلیدواژه ها:

Chimera vaccine ، HTLV-۱ ، monophosphoryl lipid A ، ISCOMATRIX ، systemic and mucosal responses